ANHGY logo

Mediclinic International plc (ANHGY)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Mediclinic International plc (ANHGY) with AI Score 44/100 (Weak). Mediclinic International plc operates a network of private hospitals across multiple countries, offering a range of healthcare services. Market cap: 0, Sector: Healthcare.

Last analyzed: Mar 18, 2026
Mediclinic International plc operates a network of private hospitals across multiple countries, offering a range of healthcare services. Established in 1983, the company has grown to become a significant player in the healthcare sector with a diverse service portfolio.
44/100 AI Score

Mediclinic International plc (ANHGY) Healthcare & Pipeline Overview

CEOCarel Aron van der Merwe D.A. M.B.Ch.B.
Employees33683
HeadquartersStellenbosch, ZA
IPO Year2020

Mediclinic International plc is a leading provider of private healthcare services, operating 74 hospitals and numerous outpatient facilities across Switzerland, South Africa, Namibia, the Middle East, and the UK, distinguished by its multidisciplinary approach and strong brand presence.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Mar 18, 2026

Investment Thesis

Mediclinic International plc presents a compelling investment thesis based on its established market presence and diversified service offerings. The company's market capitalization stands at $4.05 billion, with a price-to-earnings ratio of 26.01, indicating robust investor interest. Mediclinic's ongoing expansion of its healthcare facilities and services positions it to capitalize on the growing demand for private healthcare in its operating regions. With a profit margin of 4.7% and a gross margin of 15.6%, the company demonstrates effective cost management and operational efficiency. Key growth catalysts include the increasing prevalence of chronic diseases and an aging population, which are driving demand for specialized healthcare services. Additionally, Mediclinic's strategic investments in technology and patient care innovations are expected to enhance service delivery and patient satisfaction, further solidifying its competitive advantage in the healthcare sector. However, potential risks include regulatory challenges and economic fluctuations that could impact patient volumes and revenue growth.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market capitalization of $4.05 billion reflects strong investor confidence in the healthcare sector.
  • P/E ratio of 26.01 indicates a premium valuation relative to peers, highlighting growth expectations.
  • Profit margin of 4.7% and gross margin of 15.6% showcase operational efficiency in healthcare delivery.
  • Diverse service offerings across 74 hospitals and various outpatient facilities enhance market reach.
  • Stable employee base of 33,683 supports extensive operational capabilities and service delivery.

Competitors & Peers

Strengths

  • Extensive network of healthcare facilities across multiple regions.
  • Strong brand reputation for quality and specialized care.
  • Diverse service offerings catering to various patient needs.
  • Operational efficiencies resulting in favorable profit margins.

Weaknesses

  • Limited presence in certain high-growth emerging markets.
  • Dependence on regulatory approvals and healthcare policies.
  • Potential challenges in managing operational costs and staffing.
  • No dividend yield may deter income-focused investors.

Catalysts

  • Upcoming: Expansion of healthcare facilities in emerging markets to capture growing demand.
  • Ongoing: Implementation of technological advancements in patient care and management.
  • Ongoing: Strategic partnerships with pharmaceutical companies to enhance service offerings.
  • Upcoming: Potential regulatory changes that may favor private healthcare providers.
  • Ongoing: Continuous improvement in operational efficiencies to enhance profit margins.

Risks

  • Potential: Regulatory changes impacting operational frameworks and compliance.
  • Ongoing: Economic fluctuations affecting patient volumes and revenues.
  • Ongoing: Intense competition from other healthcare providers in key markets.
  • Potential: Currency risk associated with international operations and ADR trading.
  • Ongoing: Challenges related to staffing and operational costs in healthcare facilities.

Growth Opportunities

  • Growth opportunity 1: The increasing incidence of chronic diseases globally is anticipated to drive demand for specialized healthcare services. The global chronic disease management market is projected to reach $7 trillion by 2027, presenting a significant opportunity for Mediclinic to expand its service offerings and patient base in this growing segment.
  • Growth opportunity 2: The aging population in key markets, particularly in Europe and North America, is expected to increase the demand for healthcare services. By 2030, the number of people aged 65 and older is projected to reach 1.5 billion worldwide, creating a substantial opportunity for Mediclinic to enhance its geriatric care services and facilities.
  • Growth opportunity 3: Technological advancements in healthcare, such as telemedicine and digital health solutions, are transforming patient care delivery. Mediclinic can leverage these technologies to improve patient engagement and operational efficiency, potentially capturing a larger share of the growing digital health market, which is expected to exceed $640 billion by 2026.
  • Growth opportunity 4: Expansion into emerging markets presents a significant growth avenue for Mediclinic. With increasing healthcare access and investment in healthcare infrastructure in regions such as Africa and the Middle East, Mediclinic can establish new facilities and partnerships to tap into these high-growth markets.
  • Growth opportunity 5: Strategic partnerships and collaborations with pharmaceutical and biotechnology companies can enhance Mediclinic's service offerings. By integrating innovative therapies and treatments into its healthcare services, Mediclinic can attract a broader patient demographic and improve patient outcomes.

Opportunities

  • Growing demand for private healthcare services due to chronic diseases.
  • Expansion into emerging markets with increasing healthcare access.
  • Technological advancements improving patient care delivery.
  • Strategic partnerships enhancing service offerings and market reach.

Threats

  • Intense competition from other healthcare providers.
  • Regulatory changes impacting operational frameworks.
  • Economic fluctuations affecting patient volumes and revenues.
  • Potential risks associated with healthcare reimbursements and insurance.

Competitive Advantages

  • Strong brand recognition in the healthcare sector enhances patient trust.
  • Diverse service offerings provide a comprehensive healthcare solution.
  • Established network of facilities across multiple countries increases accessibility.
  • Commitment to quality care and patient satisfaction fosters loyalty.
  • Operational efficiencies and economies of scale reduce costs and improve margins.

About ANHGY

Founded in 1983 and headquartered in Stellenbosch, South Africa, Mediclinic International plc has established itself as a prominent player in the private healthcare sector. The company operates under the Mediclinic and Hirslanden brand names, offering a comprehensive range of specialist-oriented and multidisciplinary healthcare services. With a network of 74 hospitals, 20 day case clinics, 22 outpatient clinics, 5 subacute hospitals, and 2 mental health facilities, Mediclinic provides approximately 11,538 inpatient beds across various regions, including Switzerland, South Africa, Namibia, the Middle East, and the United Kingdom. The company’s operations extend beyond healthcare delivery; it also offers services such as treasury management, hospital equipment procurement, emergency medical services, and healthcare management. Mediclinic's commitment to high-quality patient care is reflected in its extensive facilities, which include 453 theatres and a robust management of healthcare staff. The company’s strategic focus on innovation and quality has positioned it well within the competitive landscape of private healthcare, enabling it to meet the diverse needs of its patients and adapt to the evolving healthcare environment.

What They Do

  • Operate a network of private hospitals and healthcare facilities.
  • Provide specialist-oriented and multidisciplinary healthcare services.
  • Manage outpatient clinics and day case clinics for various medical needs.
  • Offer emergency medical services and healthcare management solutions.
  • Engage in hospital equipment procurement and related services.
  • Provide mental health services and subacute care facilities.

Business Model

  • Generate revenue through patient services in private hospitals and clinics.
  • Offer specialized healthcare services to cater to diverse patient needs.
  • Engage in procurement and management services for healthcare facilities.
  • Provide ancillary services such as food and catering, and debt collection.
  • Leverage property management and intellectual property holdings for additional revenue.

Industry Context

The healthcare industry, particularly the private medical care facilities segment, is experiencing significant growth driven by an increasing demand for specialized healthcare services. The global healthcare market is projected to grow at a CAGR of approximately 7.9% from 2021 to 2028, fueled by factors such as an aging population, rising chronic disease prevalence, and advancements in medical technology. Within this competitive landscape, Mediclinic International plc stands out due to its extensive network of facilities and a strong brand reputation. Competitors such as ARHCF, ASPHF, CAKFY, DCHPF, and GALNF are also vying for market share, but Mediclinic's diverse service offerings and commitment to quality care provide a significant competitive edge.

Key Customers

  • Patients seeking private healthcare services in various regions.
  • Insurance companies providing coverage for healthcare services.
  • Government and public health organizations requiring private healthcare partnerships.
  • Corporate clients seeking employee health services and wellness programs.
  • Healthcare professionals and specialists collaborating with Mediclinic.
AI Confidence: 73% Updated: Mar 18, 2026

Financials

Chart & Info

Mediclinic International plc (ANHGY) stock price: Price data unavailable

Latest News

No recent news available for ANHGY.

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ANHGY.

Price Targets

Wall Street price target analysis for ANHGY.

MoonshotScore

44/100

What does this score mean?

The MoonshotScore rates ANHGY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Leadership: Carel Aron van der Merwe D.A. M.B.Ch.B.

CEO

Carel Aron van der Merwe holds a medical degree and has extensive experience in healthcare management. He has held various leadership roles within Mediclinic and has a strong background in clinical practice and healthcare administration, contributing to the company’s strategic direction and operational success.

Track Record: Under Carel's leadership, Mediclinic has expanded its network of facilities and enhanced its service offerings, positioning the company for sustained growth in the competitive healthcare landscape.

Mediclinic International plc ADR Information Unsponsored

An American Depositary Receipt (ADR) is a negotiable certificate issued by a U.S. bank representing shares in a foreign company's stock. ANHGY is classified as a Level 1 ADR, allowing U.S. investors to trade shares of Mediclinic International plc on the OTC market, providing easier access to international investments.

  • Home Market Ticker: Stellenbosch, ZA
  • ADR Level: 1
  • ADR Ratio: 1:1
  • Home Market Ticker: ANHG
Currency Risk: Investors holding ANHGY are exposed to currency risk due to fluctuations between the U.S. dollar and the South African rand. Changes in exchange rates can impact the value of dividends and capital gains for U.S. investors, making it essential to consider currency trends when investing.
Tax Implications: U.S. investors may be subject to a foreign dividend withholding tax rate on any dividends received from ANHGY. The tax rate varies by country, and tax treaties may apply to reduce withholding rates.
Trading Hours: The home market in South Africa operates during local trading hours, which differ from U.S. trading hours. This time difference can affect liquidity and trading volumes for ANHGY during U.S. market hours.

ANHGY OTC Market Information

The OTC Other tier includes stocks that do not meet the stringent listing requirements of major exchanges like NYSE or NASDAQ. These stocks may have lower liquidity and less stringent reporting requirements, making them accessible to a broader range of investors but potentially riskier.

  • OTC Tier: OTC Other
  • Disclosure Status: Unknown
Liquidity: The liquidity of ANHGY may be lower compared to stocks listed on major exchanges, potentially resulting in wider bid-ask spreads and trading difficulties. Investors may want to evaluate these factors when assessing their investment strategy.
OTC Risk Factors:
  • Lower liquidity compared to major exchange-listed stocks may lead to higher volatility.
  • Less stringent reporting requirements can result in less transparency.
  • Potential for wider bid-ask spreads impacting trading costs.
  • Regulatory risks associated with OTC market trading.
Due Diligence Checklist:
  • Verify the availability of recent financial statements.
  • Assess the company's competitive position within the healthcare sector.
  • Investigate the management team's experience and track record.
  • Review any recent news or developments affecting the company.
  • Evaluate the potential impact of regulatory changes on operations.
Legitimacy Signals:
  • Established brand presence in the healthcare sector.
  • Compliance with local regulations and healthcare standards.
  • Transparent communication of financial performance and strategies.
  • Recognition from industry awards and certifications.

What Investors Ask About Mediclinic International plc (ANHGY)

What does Mediclinic International plc do?

Mediclinic International plc operates a network of private hospitals and healthcare facilities, offering specialized and multidisciplinary healthcare services. The company manages a variety of healthcare services, including outpatient clinics, emergency medical services, and mental health facilities, across multiple countries.

What do analysts say about ANHGY stock?

Analysts view ANHGY as a significant player in the healthcare sector, noting its strong market presence and diversified service offerings. Key valuation metrics indicate a premium P/E ratio compared to peers, reflecting growth expectations. Analysts emphasize the company's operational efficiencies and potential for expansion in emerging markets.

What are the main risks for ANHGY?

ANHGY faces various risks, including regulatory changes that may impact its operational framework and compliance requirements. Additionally, economic fluctuations could affect patient volumes and revenues, while intense competition from other healthcare providers poses a continuous threat. Currency risk related to international operations is also a consideration for investors.

What are the key factors to evaluate for ANHGY?

Mediclinic International plc (ANHGY) currently holds an AI score of 44/100, indicating low score. Key strength: Extensive network of healthcare facilities across multiple regions.. Primary risk to monitor: Potential: Regulatory changes impacting operational frameworks and compliance.. This is not financial advice.

How frequently does ANHGY data refresh on this page?

ANHGY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven ANHGY's recent stock price performance?

Recent price movement in Mediclinic International plc (ANHGY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Extensive network of healthcare facilities across multiple regions.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider ANHGY overvalued or undervalued right now?

Determining whether Mediclinic International plc (ANHGY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying ANHGY?

Before investing in Mediclinic International plc (ANHGY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Data is sourced from company filings and market analysis as of March 2026.
Data Sources

Popular Stocks